These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
282 related articles for article (PubMed ID: 17459606)
1. Radiotherapy after prostatectomy: improved biochemical relapse-free survival with whole pelvic compared with prostate bed only for high-risk patients. Spiotto MT; Hancock SL; King CR Int J Radiat Oncol Biol Phys; 2007 Sep; 69(1):54-61. PubMed ID: 17459606 [TBL] [Abstract][Full Text] [Related]
2. Elective pelvic versus prostate bed-only salvage radiotherapy following radical prostatectomy: A propensity score-matched analysis. Song C; Kang HC; Kim JS; Eom KY; Kim IA; Chung JB; Hong SK; Byun SS; Lee SE Strahlenther Onkol; 2015 Oct; 191(10):801-9. PubMed ID: 26159555 [TBL] [Abstract][Full Text] [Related]
3. Elective pelvic irradiation in prostate cancer patients with biochemical failure following radical prostatectomy: A propensity score matching analysis. Song C; Byun SJ; Kim YS; Ahn H; Byun SS; Kim CS; Lee SE; Kim JS PLoS One; 2019; 14(4):e0215057. PubMed ID: 30973905 [TBL] [Abstract][Full Text] [Related]
4. Improved outcomes with higher doses for salvage radiotherapy after prostatectomy. King CR; Spiotto MT Int J Radiat Oncol Biol Phys; 2008 May; 71(1):23-7. PubMed ID: 18207668 [TBL] [Abstract][Full Text] [Related]
5. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy. Kupelian PA; Katcher J; Levin HS; Klein EA Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811 [TBL] [Abstract][Full Text] [Related]
9. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features. Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249 [TBL] [Abstract][Full Text] [Related]
10. Adverse risk factors for salvage radiotherapy outcomes after radical prostatectomy in prostate cancer patients. Yıldırım HC; Dinçer ST; Yaprak G; Kaydıhan N; Barlas C; Çakıroğlu N; Pekyürek M; Can G; Dinçbaş FÖ World J Urol; 2023 Jun; 41(6):1503-1509. PubMed ID: 37199814 [TBL] [Abstract][Full Text] [Related]
11. Postoperative prostate-specific antigen velocity independently predicts for failure of salvage radiotherapy after prostatectomy. King CR; Presti JC; Brooks JD; Gill H; Spiotto MT Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1472-7. PubMed ID: 17935902 [TBL] [Abstract][Full Text] [Related]
12. Elective irradiation of pelvic lymph nodes during postprostatectomy salvage radiotherapy. Moghanaki D; Koontz BF; Karlin JD; Wan W; Mukhopadhay N; Hagan MP; Anscher MS Cancer; 2013 Jan; 119(1):52-60. PubMed ID: 22736478 [TBL] [Abstract][Full Text] [Related]
13. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores. Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457 [TBL] [Abstract][Full Text] [Related]
14. Prostate Cancer Recurrence: Examining the Role of Salvage Radiotherapy Field and Risk Factors for Regional Disease Recurrence Captured on Hsu M; Shan X; Zhang R; Berlin E; Goel A; Agarwal M; Wong YN; Christodouleas JP; Vaughn DJ; Narayan V; Takvorian SU; Vapiwala N; Pantel AR; Haas NB Clin Genitourin Cancer; 2024 Aug; 22(4):102108. PubMed ID: 38843766 [TBL] [Abstract][Full Text] [Related]
15. Whole pelvis radiotherapy for pathological node-positive prostate cancer : Oncological outcome and prognostic factors. Poelaert F; Fonteyne V; Ost P; De Troyer B; Decaestecker K; De Meerleer G; De Visschere P; Claeys T; Dhondt B; Lumen N Strahlenther Onkol; 2017 Jun; 193(6):444-451. PubMed ID: 28101585 [TBL] [Abstract][Full Text] [Related]
16. The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial. Pollack A; Karrison TG; Balogh AG; Gomella LG; Low DA; Bruner DW; Wefel JS; Martin AG; Michalski JM; Angyalfi SJ; Lukka H; Faria SL; Rodrigues GB; Beauchemin MC; Lee RJ; Seaward SA; Allen AM; Monitto DC; Seiferheld W; Sartor O; Feng F; Sandler HM Lancet; 2022 May; 399(10338):1886-1901. PubMed ID: 35569466 [TBL] [Abstract][Full Text] [Related]
17. Postoperative elective pelvic nodal irradiation compared to prostate bed irradiation in locally advanced prostate cancer - a retrospective analysis of dose-escalated patients. Link C; Honeck P; Makabe A; Giordano FA; Bolenz C; Schaefer J; Bohrer M; Lohr F; Wenz F; Buergy D Radiat Oncol; 2019 Jun; 14(1):96. PubMed ID: 31174555 [TBL] [Abstract][Full Text] [Related]
18. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Lawton CA; DeSilvio M; Roach M; Uhl V; Kirsch R; Seider M; Rotman M; Jones C; Asbell S; Valicenti R; Hahn S; Thomas CR Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):646-55. PubMed ID: 17531401 [TBL] [Abstract][Full Text] [Related]
19. Factors affecting recurrence rates after prostatectomy or radiotherapy in localized prostate carcinoma patients with biopsy Gleason score 8 or above. Kupelian PA; Buchsbaum JC; Elshaikh M; Reddy CA; Zippe C; Klein EA Cancer; 2002 Dec; 95(11):2302-7. PubMed ID: 12436435 [TBL] [Abstract][Full Text] [Related]